Clinical Trial Update: A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety, tolerability, and efficacy of ARX-F02 (Sufentanil NanoTab) versus placebo for cancer breakthrough pain; results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Cancer Pain

Drugs mentioned

• ARX-F02 (Sufentanil NanoTab) (sufentanil)

Snippet

Sponsor: Talphera, Inc | Conditions: Cancer, Pain | Phase 2 | Status: COMPLETED | Results posted: 2015-01-01